Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ESSA Pharma's cash to debt ratio for the quarter that ended in Jun. 2025 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, ESSA Pharmacould pay off its debt using the cash in hand for the quarter that ended in Jun. 2025.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for ESSA Pharma's Cash-to-Debt or its related term are showing as below:
EPIX's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 7.25 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
ESSA Pharma Cash-to-Debt Related Terms
ESSA Pharma Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for ESSA Pharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, ESSA Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ESSA Pharma Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ESSA Pharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where ESSA Pharma's Cash-to-Debt falls into.
ESSA Pharma's Cash to Debt Ratio for the quarter that ended in Jun. 2025 is calculated as:
ESSA Pharma had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
ESSA Pharma (EPIX) has a Cash-to-Debt of No Debt (1) as of Jun. 2025.
Is ESSA Pharma's Cash-to-Debt too high?
ESSA Pharma's current Cash-to-Debt is No Debt (1). Overall, ESSA Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does ESSA Pharma's Cash-to-Debt compare to SLXN and NLSP?
ESSA Pharma's Cash-to-Debt of No Debt (1) can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 7.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.25, based on 1,343 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ESSA Pharma's current Cash-to-Debt is No Debt (1). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ESSA Pharma stock overvalued right now?
ESSA Pharma (EPIX) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1). ESSA Pharma's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For ESSA Pharma (EPIX), the current Cash-to-Debt is No Debt (1) as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
22GF Score
Get the complete analysis for EPIX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EPIX has been successfully added to your 
